-
1
-
-
0032874395
-
The oral fluoropyrimidines in cancer chemotherapy
-
Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 1999; 5: 2289-2296.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2289-2296
-
-
Lamont, E.B.1
Schilsky, R.L.2
-
2
-
-
13744251436
-
Systemic therapy for colorectal cancer
-
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
-
(2005)
N Engl J Med
, vol.352
, pp. 476-487
-
-
Meyerhardt, J.A.1
Mayer, R.J.2
-
3
-
-
2942648695
-
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy
-
Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214-2232.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2214-2232
-
-
Rich, T.A.1
Shepard, R.C.2
Mosley, S.T.3
-
4
-
-
0018757734
-
Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents
-
Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209-214.
-
(1979)
Gann
, vol.70
, pp. 209-214
-
-
Fujii, S.1
Kitano, S.2
Ikenaka, K.3
Shirasaka, T.4
-
5
-
-
33646443236
-
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06
-
Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2059-2064
-
-
Lembersky, B.C.1
Wieand, H.S.2
Petrelli, N.J.3
-
6
-
-
33846990133
-
Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06
-
Kopec JA, Yothers G, Ganz PA et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007; 25: 424-430.
-
(2007)
J Clin Oncol
, vol.25
, pp. 424-430
-
-
Kopec, J.A.1
Yothers, G.2
Ganz, P.A.3
-
7
-
-
0035138840
-
Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
-
Nakajima M, Kwon JT, Tanaka N et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69: 72-78.
-
(2001)
Clin Pharmacol Ther
, vol.69
, pp. 72-78
-
-
Nakajima, M.1
Kwon, J.T.2
Tanaka, N.3
-
8
-
-
21044434731
-
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy
-
Kawakami K, Graziano F, Watanabe G et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 2005; 11: 3778-3783.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3778-3783
-
-
Kawakami, K.1
Graziano, F.2
Watanabe, G.3
-
9
-
-
0642286407
-
Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis
-
Kumagai K, Hiyama K, Oyama T et al. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11: 593-600.
-
(2003)
Int J Mol Med
, vol.11
, pp. 593-600
-
-
Kumagai, K.1
Hiyama, K.2
Oyama, T.3
-
10
-
-
0032713815
-
Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations
-
Harmon DL, Shields DC, Woodside JV et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999; 17: 298-309.
-
(1999)
Genet Epidemiol
, vol.17
, pp. 298-309
-
-
Harmon, D.L.1
Shields, D.C.2
Woodside, J.V.3
-
11
-
-
0033805360
-
A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia
-
Chango A, Emery-Fillon N, de Courcy GP et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000; 70: 310-315.
-
(2000)
Mol Genet Metab
, vol.70
, pp. 310-315
-
-
Chango, A.1
Emery-Fillon, N.2
de Courcy, G.P.3
-
12
-
-
2942527225
-
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer
-
Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-515.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 501-515
-
-
Sai, K.1
Saeki, M.2
Saito, Y.3
-
13
-
-
13544260840
-
CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians
-
Vasconcelos GM, Struchiner CJ, Suarez-Kurtz G. CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. Pharmacogenomics J 2005; 5: 42-48.
-
(2005)
Pharmacogenomics J
, vol.5
, pp. 42-48
-
-
Vasconcelos, G.M.1
Struchiner, C.J.2
Suarez-Kurtz, G.3
-
14
-
-
0036016314
-
A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur
-
Daigo S, Takahashi Y, Fujieda M et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12: 299-306.
-
(2002)
Pharmacogenetics
, vol.12
, pp. 299-306
-
-
Daigo, S.1
Takahashi, Y.2
Fujieda, M.3
-
15
-
-
0036299144
-
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles
-
Xu C, Rao YS, Xu B et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 2002; 290: 318-324.
-
(2002)
Biochem Biophys Res Commun
, vol.290
, pp. 318-324
-
-
Xu, C.1
Rao, Y.S.2
Xu, B.3
-
16
-
-
33746102909
-
Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen
-
Ichikawa W, Takahashi T, Suto K et al. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12: 3928-3934.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3928-3934
-
-
Ichikawa, W.1
Takahashi, T.2
Suto, K.3
-
17
-
-
0018744377
-
Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine
-
Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res 1979; 39: 2406-2413.
-
(1979)
Cancer Res
, vol.39
, pp. 2406-2413
-
-
Houghton, J.A.1
Houghton, P.J.2
Wooten, R.S.3
-
18
-
-
0035750549
-
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
-
Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70.
-
(2001)
Pharmacogenomics J
, vol.1
, pp. 65-70
-
-
Pullarkat, S.T.1
Stoehlmacher, J.2
Ghaderi, V.3
-
19
-
-
0037990003
-
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy
-
Cohen V, Panet-Raymond V, Sabbaghian N et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611-1615.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1611-1615
-
-
Cohen, V.1
Panet-Raymond, V.2
Sabbaghian, N.3
-
20
-
-
14944380124
-
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity
-
Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-1369.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1365-1369
-
-
Jakobsen, A.1
Nielsen, J.N.2
Gyldenkerne, N.3
Lindeberg, J.4
-
21
-
-
4444339951
-
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy
-
Lecomte T, Ferraz JM, Zinzindohoue F et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10: 5880-5888.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5880-5888
-
-
Lecomte, T.1
Ferraz, J.M.2
Zinzindohoue, F.3
-
22
-
-
38949175429
-
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients
-
Sharma R, Hoskins JM, Rivory LP et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008; 14: 817-825.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 817-825
-
-
Sharma, R.1
Hoskins, J.M.2
Rivory, L.P.3
-
23
-
-
0142150084
-
Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer
-
Chen J, Hunter DJ, Stampfer MJ et al. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 958-962.
-
(2003)
Cancer Epidemiol Biomarkers Prev
, vol.12
, pp. 958-962
-
-
Chen, J.1
Hunter, D.J.2
Stampfer, M.J.3
-
24
-
-
0027945196
-
Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy
-
Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994; 12: 2239-2242.
-
(1994)
J Clin Oncol
, vol.12
, pp. 2239-2242
-
-
Diasio, R.B.1
Lu, Z.2
-
25
-
-
0023902287
-
Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
-
Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47-51.
-
(1988)
J Clin Invest
, vol.81
, pp. 47-51
-
-
Diasio, R.B.1
Beavers, T.L.2
Carpenter, J.T.3
-
26
-
-
0034901306
-
Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency
-
van Kuilenburg AB, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1149-1153
-
-
van Kuilenburg, A.B.1
Muller, E.W.2
Haasjes, J.3
-
27
-
-
0035074119
-
Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil
-
Yamaguchi K, Arai Y, Kanda Y, Akagi K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 2001; 92: 337-342.
-
(2001)
Jpn J Cancer Res
, vol.92
, pp. 337-342
-
-
Yamaguchi, K.1
Arai, Y.2
Kanda, Y.3
Akagi, K.4
-
29
-
-
7344249042
-
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
-
Ridge SA, Sludden J, Brown O et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 1998; 46: 151-156.
-
(1998)
Br J Clin Pharmacol
, vol.46
, pp. 151-156
-
-
Ridge, S.A.1
Sludden, J.2
Brown, O.3
-
30
-
-
36249014288
-
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients
-
Zhang H, Li YM, Jin X. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 2007; 24: 251-258.
-
(2007)
Med Oncol
, vol.24
, pp. 251-258
-
-
Zhang, H.1
Li, Y.M.2
Jin, X.3
-
31
-
-
0022656553
-
Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes
-
Peters GJ, Laurensse E, Leyva A et al. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986; 46: 20-28.
-
(1986)
Cancer Res
, vol.46
, pp. 20-28
-
-
Peters, G.J.1
Laurensse, E.2
Leyva, A.3
-
32
-
-
43749114271
-
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group
-
Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2131-2138
-
-
Schwab, M.1
Zanger, U.M.2
Marx, C.3
-
33
-
-
47849131155
-
The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer
-
Capitain O, Boisdron-Celle M, Poirier AL et al. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 2008; 8: 256-267.
-
(2008)
Pharmacogenomics J
, vol.8
, pp. 256-267
-
-
Capitain, O.1
Boisdron-Celle, M.2
Poirier, A.L.3
-
34
-
-
0034904708
-
The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations
-
Gaughan DJ, Kluijtmans LA, Barbaux S et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001; 157: 451-456.
-
(2001)
Atherosclerosis
, vol.157
, pp. 451-456
-
-
Gaughan, D.J.1
Kluijtmans, L.A.2
Barbaux, S.3
-
35
-
-
0036562507
-
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy
-
Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1: 545-552.
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 545-552
-
-
Niyikiza, C.1
Baker, S.D.2
Seitz, D.E.3
-
36
-
-
0021223573
-
Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil
-
Kawata S, Minami Y, Tarui S et al. Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil. Jpn J Pharmacol 1984; 36: 43-49.
-
(1984)
Jpn J Pharmacol
, vol.36
, pp. 43-49
-
-
Kawata, S.1
Minami, Y.2
Tarui, S.3
-
37
-
-
34250202527
-
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28
-
Minami H, Sai K, Saeki M et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007; 17: 497-504.
-
(2007)
Pharmacogenet Genomics
, vol.17
, pp. 497-504
-
-
Minami, H.1
Sai, K.2
Saeki, M.3
-
38
-
-
39149141390
-
Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients
-
Sai K, Saito Y, Sakamoto H et al. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 2008; 261: 165-171.
-
(2008)
Cancer Lett
, vol.261
, pp. 165-171
-
-
Sai, K.1
Saito, Y.2
Sakamoto, H.3
-
39
-
-
33748925080
-
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer
-
Araki K, Fujita K, Ando Y et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006; 97: 1255-1259.
-
(2006)
Cancer Sci
, vol.97
, pp. 1255-1259
-
-
Araki, K.1
Fujita, K.2
Ando, Y.3
-
40
-
-
10744221779
-
A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia
-
Danoff TM, Campbell DA, McCarthy LC et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 2004; 4: 49-53.
-
(2004)
Pharmacogenomics J
, vol.4
, pp. 49-53
-
-
Danoff, T.M.1
Campbell, D.A.2
McCarthy, L.C.3
-
41
-
-
0028867826
-
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
-
Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
-
(1995)
N Engl J Med
, vol.333
, pp. 1171-1175
-
-
Bosma, P.J.1
Chowdhury, J.R.2
Bakker, C.3
-
42
-
-
0028904620
-
Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome
-
Aono S, Adachi Y, Uyama E et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 1995; 345: 958-959.
-
(1995)
Lancet
, vol.345
, pp. 958-959
-
-
Aono, S.1
Adachi, Y.2
Uyama, E.3
-
43
-
-
0021822511
-
Pharmacology of mitoxantrone: mode of action and pharmacokinetics
-
Alberts DS, Peng YM, Bowden GT et al. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 1985; 3: 101-107.
-
(1985)
Invest New Drugs
, vol.3
, pp. 101-107
-
-
Alberts, D.S.1
Peng, Y.M.2
Bowden, G.T.3
|